EcoDrugPlus

Platelet Activating Factor Receptor

Ensembl ID : ENSGFOG00000002971
Gene Symbol: PTAFR
1 Cross references
224 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSGFOG00000005584
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSGFOG00000000122
Gene Symbol: PDGFRB
3 Cross references
247 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSGFOG00000004960
Gene Symbol: PDGFB
1 Cross references
261 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Polo Like Kinase 1

Ensembl ID : ENSGFOG00000006396
Gene Symbol: PLK1
3 Cross references
188 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Polo Like Kinase 4

Ensembl ID : ENSGFOG00000013255
Gene Symbol: PLK4
1 Cross references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSGFOG00000005482
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSGFOG00000000396
Gene Symbol: PARP3
1 Cross references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSGFOG00000010886
Gene Symbol: KCNMA1
3 Cross references
284 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSGFOG00000009487
Gene Symbol: KCNJ11
1 Cross references
189 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSGFOG00000014266
Gene Symbol: KCNJ2
1 Cross references
277 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSGFOG00000012763
Gene Symbol: KCNJ3
1 Cross references
224 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).